drugset / Trial / NCT03942068
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study was designed to evaluate the efficacy and safety of apatinib with albumin-bound paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2020-09-01
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |